DBI and cancer: Moreover, orthotopic Hep55.1C cancers responded to treatment with a combination of anti-ACBP mAb plus ferroptosis induction (with RSL3 or IKE) more efficiently than to standalone therapies with either anti-ACBP mAb or ferroptosis inducers (Figures 7E–7P and S15D).